Ascentage Pharma Group International - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AAPG Nasdaq 2836 www.ascentage.cn

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ascentage Pharma Group International

Ascentage Pharma to Participate in Four Upcoming Investor Conferences - Sep 2nd, 2026 6:00 am
Ascentage Pharma Group International (SEHK:6855) Could Be 18% Undervalued After Half Year Losses - Aug 27th, 2026 11:07 pm
ASCENTAGE PHARMA GROUP INTERNATIONAL Q2 2026 Earnings Call Summary - Aug 21st, 2026 6:30 am
Ascentage Pharma Group International H1 Earnings Call Highlights - Aug 20th, 2026 9:04 am
Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates - Aug 19th, 2026 5:00 pm
Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit - Aug 13th, 2026 6:00 am
CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 - Aug 5th, 2026 7:07 am
Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 - Aug 5th, 2026 6:00 am
Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer - Aug 2nd, 2026 5:30 pm
Wall Street Analysts Predict a 160.09% Upside in Ascentage Pharma Group International - Unsponsored ADR (AAPG): Here's What You Should Know - Jul 27th, 2026 7:55 am
Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 - Jul 26th, 2026 5:30 pm
How Much Upside is Left in Ascentage Pharma Group International - Unsponsored ADR (AAPG)? Wall Street Analysts Think 152.23% - Jul 9th, 2026 7:55 am
Why Ascentage Pharma Group Internat (AAPG) Is Gaining Attention in Cancer Drug Development - Jun 30th, 2026 7:20 am
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress - Jun 14th, 2026 5:30 pm
A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price Weakness - Jun 8th, 2026 6:05 am
Ascentage Pharma (AAPG) Reports Phase 1b Olverembatinib Data - Jun 5th, 2026 3:03 pm
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 - May 31st, 2026 5:30 pm
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 - May 31st, 2026 5:30 pm
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 - May 31st, 2026 5:30 pm
Global Growth Companies Insiders Favor With Up To 40% Earnings Growth - May 25th, 2026 3:35 am